R&D/Clinical Trials

Webinar Date/Time: Thursday, May 23, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

PIONEER AF-PCI exploratory trial found that elderly patients experienced a lower rate of clinically significant bleeding after 12 months of treatment with Xarelto (rivaroxaban).

Webinar Date/Time: Thursday, May 9, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Early results have demonstrated that mRNA-3927 has led to a 70% reduction in the relative risk for metabolic decompensation events in patients with propionic acidemia.

Webinar Date/Time: Wednesday, May 15th, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Erickson discusses his work developing unique, targeted autologous and allogeneic T cell therapeutics.

Company says it remains committed to advancing research for immune-mediated diseases and intends to share trial data at a later date.

The conversation took place during the Veeva R&D Summit in Boston.

Webinar Date/Time: Thursday, April 18, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Reportedly, the oral weight loss pill VK2735 showed promising signs of effectiveness and a tolerable safety profile.

Spinoff seeks to aid pharmaceutical companies in accelerating early clinical development programs.

Despite not having a positive outcome, safety profiles for Keytruda and Lynparza were consistent with previous findings.

Although research on cannabinoids is now allowed in a growing number of countries, there are still a number of restrictions and corresponding licenses and permits required to work with these chemicals.

Resubmission plan comes amid feedback and a complete response letter issued by the FDA in 2019 for sotagliflozin in the treatment of glycemic control in type 1 diabetes patients with chronic kidney disease.

Submission is based on positive results from the company’s Phase III QUASAR clinical trial, in which Tremfya (guselkumab) produced positive results treating moderately to severely active ulcerative colitis.

The trial of a pharmaceutical-grade CBD for social anxiety disorder, which was the first of its kind to be approved by the FDA, is expected to receive top line results next month.

Ricciardi discusses how new treatments require much more specific patient groups in studies.

First of its kind study reported major improvements in skin clarity and itch relief in over two-thirds of participants.

Relyvrio did not significantly alter amyotrophic lateral sclerosis disease progression as measured by the ALSFRS-R total score at Week 48 compared to placebo.

Results from Phase IV RESPOND study indicate a significant reduction in plasma neurofilament light chain (NfL) levels.

Agreement to focus on research, option, and licensing for discovery of dual tumor-associated antigen-targeting antibodies.

Novel formulation of cabotegravir (CAB-ULA) allows for dosing intervals of at least four months.

Rus discusses his company’s work with neuroplastogens and how they differ from similar, psychedelic treatments.

Teens to be included in both placebo and open label studies for QRX003, a potential treatment for Netherton syndrome.

Phase III DAYBREAK study found consistent safety with Zeposia in patients with relapsing forms of multiple sclerosis.

Simon discusses a recent survey ICON conducted with professionals in obesity-related clinical research.

IDP-023 is a highly potent natural killer cell platform under evaluation for patients with multiple myeloma and non-Hodgkin lymphoma.

Abrysvo was found to produce durable efficacy against respiratory syncytial virus across two seasons in adults 60 years of age and older.

The trial reportedly showcased significant weight reduction in those treated with VK2735, a dual GLP-1/GIP receptor agonist.

NVL-520 is a novel, brain-penetrant, ROS1-selective tyrosine kinase inhibitor under evaluation for patients with metastatic ROS1-positive non–small cell lung cancer.